EMBRYOMIC LIMITED

Embryomic Limited is a pioneering life‑science company that bridges advanced proteomics and metabolomics research with everyday fertility practice. Drawing on two decades of scientific investigation, the firm has developed a proprietary, non‑invasive blastocyst‑selection test that analyses spent blastocyst media to estimate each embryo’s implantation potential. This innovative tool, now marketed as PMT‑BC (formerly BESST), equips embryologists and clinicians with rapid, data‑driven insight just before embryo transfer, helping to shorten the time to pregnancy for IVF patients.

The PMT‑BC assay is simple to implement yet highly effective – clinical data show a 47 % increase in transfer‑to‑pregnancy success compared with standard approaches. By delivering an ultrafast, non‑invasive screening method, Embryomic enables fertility teams to make more confident selection decisions, ultimately improving outcomes for couples undergoing assisted reproduction. Training is provided to ensure seamless integration of the test into existing laboratory workflows, positioning Embryomic as a trusted partner in the quest for higher IVF success rates.